I am a Reader in Radiobiology at King's College London and have in the past worked as a

• Postdoctoral researcher at King's College London (radionuclide imaging of multiple myeloma)
• Roche postdoctoral fellow at the Radboud UMC, the Netherlands (radionuclide imaging of tumour microenvironment and arthritis)
• Postdoctoral researcher at University of Oxford (targeted radionuclide therapy and the effect of chromatin density)
• PhD student at the University of St Andrews (how chromosomes are damaged after external beam irradiation)

My thesis can be viewed at https://research-repository.st-andrews.ac.uk/bitstream/10023/873/6/Samantha%20Terry%20PhD%20thesis.pdf

My research focusses on determining how radionuclides used for therapy affect either the cells they are targeting or off-target cells in order to determine how we can best use these radionuclides. My work is mostly in vitro and preclinical, with some aspects of clinical translation. Questions that I would like to answer for a whole range of radionuclides, including those used in imaging, are:

• How can therapeutic radionuclides be used to maximize tumour cell kill for the same amount of radioactivity whilst minimizing damage to healthy tissues?
• How important is subcellular localisation?
• Are radionuclides more effective in metastases?
• Does bystander play a role in radionuclide therapy?
• How can radionuclides be made more effective, in terms of combination therapies?
• Are different cells more sensitive to certain types of radiation than others?